About: Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children's hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $0.39 (+9.00%)
MBIO NASDAQ Mustang Bio Inc
Mustang Bio Inc share price
Atividade de preço de MBIO
Último preço
$ 0,390
Variação (24h)
0,03 USD (9,00%)
Volume
44.65K
Volume (média 4 sem.)
-
Abertura
$ 0,39
Variação do dia
$ 0,37 - $ 0,41
Fechamento anterior
$ 0,36
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
MBIO price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals